Biological, psychological and social markers of fibromyalgia syndrome

Not Applicable

Completed

• Conditions: Signs and Symptoms; Fibromyalgia

• Registration Number: ISRCTN24645566
• Lead Sponsor: ando and Elsa Peretti Foundation International

Brief Summary

2020 Results article in https://www.ncbi.nlm.nih.gov/pubmed/32098316 results (added 03/04/2020) 2023 Results article in https://doi.org/10.3390/biomedicines11030931 Qualitative results (added 10/01/2024)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-12-10
• Study Completion: 2020-03-08
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

1. Diagnosed with fibromyalgia, according to both 1990 and 2010 ACR criteria
2. Aged 18-65 years

Exclusion Criteria

Patients who are treated with opioids

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The following are assessed at the first clinical visit (between 0-12 months):<br>1. Gene expression analysis of the µ opioid receptor, assessed using real-time PCR using blood samples<br>2. Protein expression analysis of the µ opioid receptor, assessed using Western blotting using blood samples<br>3. Immunophenotype of the µ opioid receptor, assessed using blood samples<br>4. Functional receptor analysis, assessed using ELISA using blood samples